AusIndustry has approved Cyclopharm Limited’s (ASX: CYC) inclusion of certain expensed costs associated with its overseas research and domestic development activities as part of its application for a research and development tax incentive.
Cyclopharm confirms it has completed its Research and Development Tax incentive claim for the 2020 financial year and has been notified that it will receive a cash payment of $3.10 million (vs 2019: $3.01 million).
For more information, download the attached PDF.
Download this document
